- Semaglutide, a glucagon-like peptide-1 analogue, was associated with better glycemic control and greater reductions in body weight compared with liraglutide in adult patients with type 2 diabetes (T2D).
Why this matters
- Patients with T2D have difficulty achieving optimal control of blood glucose if they are also overweight or obese.
- Adults with T2D who were taking 1-3 oral glucose-lowering drugs were randomly assigned:
- Once-weekly semaglutide 1.0 mg (n=290).
- Once-daily liraglutide 1.2 mg (n=287).
- Change in HbA1c from baseline to week 30 comprised the primary efficacy endpoint.
- Confirmatory secondary endpoint was change in body weight at week 30.
- Funding: Novo Nordisk.
- Compared with mean baseline HbA1c (8.2%), treatment with semaglutide was associated with a greater percentage-point reduction in HbA1c by week 30 vs liraglutide (1.7%-point change vs 1.0%-point change; estimated treatment difference [ETD], −0.69% point; 95% CI, −0.82 to −0.56; P<.0001>
- A greater proportion of semaglutide-treated patients achieved HbA1c
- More patients in the semaglutide arm also achieved weight loss of ≥5% (55.9% vs 17.7%; OR, 5.89; P<.0001 and vs or p>
- Slightly more adverse events were observed in the semaglutide group (70.6% vs 66.2%).
- Lack of participant lifestyle data.